Navigation Links
Immucor Responding to FTC Inquiry
Date:10/26/2007

NORCROSS, Ga., Oct. 26 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq/NM: BLUD), a global provider of automated instrument-reagent systems to the blood transfusion industry, announced today that on October 12, 2007, the company received a letter from the Federal Trade Commission ("FTC") requesting that the company voluntarily provide certain documents and information to the FTC concerning three acquisitions made by Immucor in the period from 1996 through 1999, and concerning Immucor's product pricing activities since then. The letter states that the request is part of a non- public investigation by the FTC of whether Immucor violated federal antitrust laws or engaged in unfair methods of competition through those acquisitions, and whether Immucor or others engaged in unfair methods of competition by restricting price competition. The FTC letter states that neither the letter nor the existence of the investigation indicates that the FTC has concluded that Immucor or anyone else has violated the law.

The company intends to cooperate with the FTC in this investigation, and is in the process of responding to the FTC's request. At this time the company cannot reasonably assess the timing or outcome of the investigation or its effect, if any, on the company's business.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at http://www.immucor.com.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Its in the mail -- Responding to an FDA warning letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
Breaking Biology Technology:
(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):